MedTrace Logo

Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values

NCT01483950 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2013-02-05

No results posted yet for this study

Summary

This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for at least 6 months. Data collection for each patient will take place at a single visit. The investigators will complete Case Report Form (CRF) with patient's demographic, the presence of the factors for high cardiovascular risk, current treatment, cholesterol value as well as with further treatment decision.

Conditions

  • Hypercholesterolaemia

Sponsors & Collaborators

Principal Investigators

  • Vesna Loza, DOC. DR. SCI. MED · Klinika za bolesti srca i reumatizma Sarajevo , Bosnia and Herzegovina

  • Meta Jeras, MR PH · West Balkan MD

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Bosnia and Herzegovina

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01483950 on ClinicalTrials.gov